跳至主要内容
临床试验/NCT07126132
NCT07126132已完成不适用

The Hemopexin-Apolipoprotein B Product: A Novel Biomarker Integrating Oxidative Stress and Lipid Metabolism for Coronary Artery Disease Risk Stratification

Shiyan City Renmin Hospital1 个研究点 分布在 1 个国家目标入组 460 人开始时间: 2019年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
460
试验地点
1
主要终点
Odds Ratio for the Presence of Coronary Artery Disease per Unit Increase in Hpx•apoB Product

研究概览

简要总结

This was a single-center, cross-sectional study designed to investigate a novel composite biomarker, the Hemopexin-Apolipoprotein B (Hpx•apoB) product, for its association with coronary artery disease (CAD). The study aimed to determine if the Hpx•apoB product could serve as an independent predictor for the presence and severity of CAD and to evaluate its incremental value in improving risk stratification when added to existing clinical risk models.

详细描述

The pathophysiology of coronary artery disease (CAD) involves complex interactions between lipid dysregulation and oxidative stress. This study proposed and evaluated a novel composite biomarker, the Hemopexin-Apolipoprotein B (Hpx•apoB) product, which integrates a marker of atherogenic particle burden (apoB) with a marker reflecting the systemic response to heme-induced oxidative stress (Hpx). From January 2019 to December 2023, a total of 460 participants were enrolled: 350 patients with angiographically confirmed CAD (≥50% stenosis in a major coronary artery) and 110 control subjects without significant stenosis. Plasma Hpx was quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The study used multivariate logistic regression to assess the independent association between the Hpx•apoB product and CAD. Furthermore, its incremental diagnostic value was evaluated by calculating the area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI) when added to conventional risk factors and established risk scores (Framingham Risk Score and SCORE2).

研究设计

研究类型
Observational
观察模型
Case Crossover
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged ≥18 years.
  • Referred for coronary angiography due to suspected or known CAD.
  • Provided written informed consent.

排除标准

  • Acute infectious or systemic inflammatory diseases.
  • Severe hepatic or renal dysfunction (eGFR < 30 mL/min/1.73m²).
  • Malignancy.
  • Autoimmune disease.
  • A history of major surgery within the past three months.

结局指标

主要结局

Odds Ratio for the Presence of Coronary Artery Disease per Unit Increase in Hpx•apoB Product

时间窗: Baseline

This outcome assesses the strength of association between the biomarker and CAD. The plasma concentration of the Hpx•apoB product (Unit: mg²/L²) was used as a continuous variable in a multivariable logistic regression model to predict the presence of CAD. The result is expressed as an Odds Ratio (OR), a unitless measure, with a 95% confidence interval.

Change in Area Under the Receiver Operating Characteristic Curve (AUC)

时间窗: Baseline

This outcome measures the incremental predictive value of the Hpx•apoB product. The AUC of a baseline risk model (containing hs-CRP and LDL-C) was compared to the AUC of the same model with the Hpx•apoB product added. The change in AUC (ΔAUC) quantifies the improvement in model discrimination. AUC is a unitless value ranging from 0.5 to 1.0.

次要结局

  • Comparison of Hpx•apoB Product Concentration by Number of Diseased Vessels(Baseline)
  • Correlation Between Hpx•apoB Product and Gensini Score(Baseline)
  • Correlation Between Hpx•apoB Product and High-Sensitivity C-Reactive Protein (hs-CRP)(Baseline)
  • Correlation Between Hpx•apoB Product and Low-Density Lipoprotein Cholesterol (LDL-C)(Baseline)
  • Correlation Between Hpx•apoB Product and Triglycerides (TG)(Baseline)
  • Correlation Between Hpx•apoB Product and Estimated Glomerular Filtration Rate (eGFR)(Baseline)

研究者

发起方
Shiyan City Renmin Hospital
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Qunxiong Fan

Principal investigator

Shiyan City Renmin Hospital

研究点 (1)

Loading locations...

相似试验

Hpx•apoB Product as a Biomarker for Coronary Artery... | 临床试验